title: Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors.
abstract: BACKGROUND
  Hepatocellular carcinoma (HCC) typically recurs following primary treatment. The primary objective of this systematic review was to evaluate the safety and efficacy of ablative therapies for recurrent HCC. The secondary objective was to identify any factors associated with prognosis following ablation for recurrent disease.
  
  
  METHODS
  A systematic search of the literature published between January 2000 and December 2013 was undertaken using the PubMed, Medline and Scopus databases. Reference lists from selected studies were manually searched to ensure complete capture of any relevant data.
  
  
  RESULTS
  A total of 19 studies were included in the review. The median age of patients undergoing ablation for recurrent HCC was 58 years (range 52-69 years) and 85 % of patients had cirrhosis (range 56-100 %). HCC recurred as a single nodule in 79 % of those treated with ablation (range 46-100 %). There were few significant complications associated with any form of ablation. Sufficient data were only available to allow analysis of survival outcomes following radiofrequency ablation (RFA). After RFA the median, 1, 3 and 5-year survivals were 84 % (73-99 %), 51 % (42-84 %) and 40 % (28-83 %), respectively. The only factor consistently associated with overall survival following ablation for recurrence was the alpha-fetoprotein (AFP) level.
  
  
  CONCLUSIONS
  Comparable survival figures from previously published systematic reviews suggest that hepatic resection is the most effective treatment for recurrent HCC. However, ablation can be a safe and effective option for the majority of patients with recurrent disease who are unsuitable for surgery. Elevated levels of AFP suggest a poorer prognosis following ablation.
authors: Department of Hepatobiliary and Pancreatic Surgery, University Hospitals of Leicester, Gwendolen Road, Leicester, LE5 4PW, UK, sarah.thomasset@uhl-tr.nhs.uk.
authors: S C
authors: SC
authors: Thomasset
authors: A R
authors: AR
authors: Dennison
authors: G
authors: G
authors: Garcea
mesh_terms: D055011:Ablation Techniques / Q000009:adverse effects*; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D017115:Catheter Ablation; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000601:surgery*; D011379:Prognosis; D015996:Survival Rate; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D000509:alpha-Fetoproteins
references: Hepatology. 2011 Mar;53(3):1020-2
references: 21374666
references: Clin Radiol. 2005 Sep;60(9):1018-25
references: 16124984
references: Radiology. 2004 Jan;230(1):135-41
references: 14631050
references: AJR Am J Roentgenol. 2006 May;186(5 Suppl):S275-83
references: 16632688
references: World J Surg. 2011 Jan;35(1):170-7
references: 20922387
references: Ann Surg Oncol. 2011 Dec;18(13):3650-6
references: 21674268
references: Am J Gastroenterol. 2007 Aug;102(8):1661-70; quiz 1660, 1671
references: 17555459
references: Eur J Radiol. 2008 Aug;67(2):336-47
references: 17765421
references: Int J Cancer. 2001 Oct 15;94(2):153-6
references: 11668491
references: Cancer. 2005 Mar 15;103(6):1201-9
references: 15690326
references: Ann Hepatol. 2010 Jan-Mar;9(1):23-32
references: 20308719
references: Eur J Surg Oncol. 2009 Feb;35(2):174-9
references: 18325724
references: Radiology. 2009 Sep;252(3):905-13
references: 19567647
references: Int J Surg. 2011;9(2):188-91
references: 21093616
references: Hepatogastroenterology. 2001 Sep-Oct;48(41):1401-5
references: 11677974
references: Hepatology. 1992 Oct;16(4):906-11
references: 1328010
references: Ann Surg Oncol. 2008 Dec;15(12):3484-93
references: 18679754
references: Hepatogastroenterology. 1993 Aug;40(4):320-3
references: 8406299
references: Liver Transpl. 2013 Apr;19(4):411-9
references: 23447460
references: Eur J Surg Oncol. 2010 Mar;36(3):257-63
references: 19643561
references: Anticancer Res. 2012 Nov;32(11):5059-65
references: 23155279
references: Radiology. 2012 Feb;262(2):689-700
references: 22157201
references: Ann Surg. 1999 Feb;229(2):216-22
references: 10024103
references: World J Surg. 2012 Jan;36(1):151-6
references: 22030561
references: Surg Oncol. 2013 Jun;22(2):e23-30
references: 23535302
references: Zhonghua Yi Xue Za Zhi. 2006 Mar 28;86(12):801-5
references: 16681964
references: Clin Radiol. 2013 Jan;68(1):21-6
references: 22766484
references: Lancet. 1997 Oct 18;350(9085):1142-3
references: 9343506
references: Technol Health Care. 2013;21(1):9-18
references: 23358055
references: Ann Surg Oncol. 2012 Dec;19(13):4300-6
references: 22766980
references: Ann Surg. 2006 Mar;243(3):321-8
references: 16495695
references: Eur Radiol. 2007 Mar;17(3):684-92
references: 17093964
references: World J Surg Oncol. 2010 Jul 01;8:55
references: 20591196
references: Br J Surg. 2005 Nov;92(11):1393-8
references: 16044409
references: Arch Surg. 1996 Jan;131(1):71-6
references: 8546582
references: Ann Surg Oncol. 2007 Aug;14 (8):2319-29
references: 17522947
references: Surgery. 2012 May;151(5):700-9
references: 22284764
references: N Engl J Med. 1999 Mar 11;340(10):745-50
references: 10072408
references: Hepatology. 2011 Jan;53(1):136-47
references: 20967759
references: Hepatol Res. 2009 Mar;39(3):231-40
references: 19054154
references: Ann Surg. 2013 Apr;257(4):686-92
references: 23426335
references: Cardiovasc Intervent Radiol. 2014 Jun;37(3):705-15
references: 23912493
references: J Hepatol. 2012 Apr;56(4):908-43
references: 22424438